TY - JOUR
T1 - Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient
AU - Glück, Stefan
AU - Arteaga, Carlos L.
AU - Osborne, C. Kent
PY - 2011/9/1
Y1 - 2011/9/1
N2 - The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.
AB - The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.
UR - http://www.scopus.com/inward/record.url?scp=80052516349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052516349&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-2051
DO - 10.1158/1078-0432.CCR-10-2051
M3 - Article
C2 - 21764887
AN - SCOPUS:80052516349
SN - 1078-0432
VL - 17
SP - 5559
EP - 5561
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 17
ER -